Recently, we [13] and others [14, 15], have shown that targeted alpha therapy (TAT) using 225Ac labeled anti-CD38 antibodies (225Ac-CD38 TAT) can be an effective and minimally toxic therapeutic strategy to eradicate MM. Here, CD38 is linked to Miyoshi myopathy.